1. Home /
  2. Life Sciences

Life Sciences

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.

Tilray Shares Surge on Novartis Distribution Deal

Tilray Shares Surge on Novartis Distribution Deal

Canadian cannabis producer's stock jumps on announcement that it's teaming up with Novartis's Sandoz until to sell and distribute medical cannabis products globally.

DowDuPont Regains Some Footing but Still Could Retest Recent Lows

DowDuPont Regains Some Footing but Still Could Retest Recent Lows

A key chart suggests further gains in the chemical giant are possible, but be aware that it could explore lower levels of October again.

As Canada OKs Pot, Research Advances Could Follow

As Canada OKs Pot, Research Advances Could Follow

As Canada becomes the second country after Uruguay to allow recreational use of cannabis, advances in pot research could follow.

Eli Lilly's FDA-Approved Migraine Drug is Welcomed by the 38 Million Sufferers

Eli Lilly's FDA-Approved Migraine Drug is Welcomed by the 38 Million Sufferers

With 38 million Americans suffering from migraines, the FDA's approval of Eli Lilly's preventative migraine drug Emgality can help them get their lives back. We spoke with Christi Shaw, president, Lilly Bio-Medicines for all the details.

Video: Jim Cramer Reacts to Biogen's Surge

Video: Jim Cramer Reacts to Biogen's Surge

Biogen shares rose 15% Friday following upbeat results from an Alzheimer's drug test.

Can a Bold Name Change Help Valeant Escape Its Tarnished Reputation?

Can a Bold Name Change Help Valeant Escape Its Tarnished Reputation?

Valeant will become Bausch Health Cos. this summer. Here's what that could mean for the company as it continues to recover from controversy.

It's Dumb to Think Legalizing Weed Is Still a Political Issue

It's Dumb to Think Legalizing Weed Is Still a Political Issue

What was once a red and blue issue has now attracted a growing set of proponents from both sides of the aisle.

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.